Ying Peng

Title: Innovations of Ying Peng in SARS Research

Introduction

Ying Peng is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of medical research, particularly in the area of therapeutic agents for Severe Acute Respiratory Syndrome (SARS). With a total of 2 patents, his work has the potential to impact public health significantly.

Latest Patents

Ying Peng's latest patents focus on the inhibition of SARS-associated coronavirus (SCoV) infection and replication through RNA interference. The inventions relate to therapeutic agents that are useful for treating SARS in humans. Specifically, these RNA interference (RNAi) molecules are designed to inhibit the infection and replication of the hSARS virus. The RNAi molecules target the replicase region of the hSARS virus or combinations of different sites within the hSARS virus genes. Furthermore, the patents encompass methods for using these RNAi molecules to prevent and treat SARS, including vaccines and kits that contain therapeutically effective amounts of the RNAi molecules.

Career Highlights

Ying Peng is affiliated with The University of Hong Kong, where he conducts his research and develops his innovative solutions. His work is crucial in the ongoing fight against viral infections, particularly in the context of global health crises.

Collaborations

Ying Peng has collaborated with notable researchers such as Hsiang-Fu Kung and Ming-Liang He. These collaborations have likely enhanced the scope and impact of his research efforts.

Conclusion

Ying Peng's contributions to the field of SARS research through his innovative patents demonstrate his commitment to advancing medical science. His work not only addresses immediate health concerns but also paves the way for future therapeutic developments.